To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Sulfonylureas For Diabetes Hazardous at Higher Doses URL: http://www.pslgroup.com/dg/1D0ACE.htm Doctor's Guide May 8, 2000
OLNEY, MD -- May 8, 2000 -- The National Diabetes Center -- a not-for-profit patient advocacy group for physicians located north of DC -- announced that a meta-analysis of diabetes studies suggested that higher doses of a class of drugs known as sulfonylureas are associated with increased mortality. Sulfonylulureas represent a class of drugs which bind to receptors controlling the ATP-sensitive "potassium channel" -- the major control of voltage differences across the cellular membrane. Identified previously as "SUR-1" (for "SulfonylUrea Receptor-1" found initially in the insulin-producing cells of the pancreas and also in the hypothalamus) this receptor is the physiological leptin response element. Leptin is a hormone released by fat cells in direct proportion to cell size (degree of adiposity) and when it binds to this receptor in the pancreas, it opens the potassium channel thereby inhibiting insulin release. This is likely the major mechanism whereby obesity causes type 2 diabetes. The major pharmacologic response to this abnormality has been the use of sulfonylureas, which close these same potassium channels thereby offsetting the leptin inhibition and increasing insulin release. Unfortunately another sulfonylurea receptor ("SUR-2") also exists in the vascular smooth muscle cells which control blood flow to the heart and other muscles based on metabolic demand. The effect of closing these SUR-2 potassium channels is to diminish blood flow to the heart. Although sulfonylurea agents differ in their affinity to bind to these SUR-2 receptors, the binding of all agents is increased at higher concentrations. The question that epidemiologists set out to answer was therefore, "Are higher doses of sulfonylureas associated with increased cardiovascular mortality?" The group reviewed data from seven major studies -- (1) the UGDP study in the United States, (2) the UKPDS study in Great Britain, (3) the metformin pivotal trials for registration with the FDA, (4) the Digami study of patients with myocardial infarction in Sweden, (5) the Neufeld study in Israel and (6) the Melander Study in Uppsala, Sweden and (7) the Campbell studies of sulfonylurea-induced hypoglycemic mortality. The result of this meta-analysis is that mortality was seen to associate most strongly with sulfonylurea dosage. The further enhancement of mortality seen in combination of sulfonylureas with metformin -- another class of potent oral hypoglycemic agents -- was seen to correlate not only with sulfonylurea dosage, but also with degree of control and other likely-surrogates for hypoglycemia. The National Diabetes Center has therefore issued a warning this day not to utilize any of the agents which close ATP-sensitive potassium channels in doses higher than 2.5 mg/day equivalent glipizide activity (or daily doses of 2.5 mg glyburide, 100 mg chlorpropamide, 1 mg glimepiride, 1.5 mg repaglinide.) --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.